HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The interleukin-17 receptor plays a gender-dependent role in host protection against Porphyromonas gingivalis-induced periodontal bone loss.

Abstract
Interleukin-17 (IL-17) is a proinflammatory cytokine secreted by the newly described CD4(+) Th17 subset, which is distinct from classic Th1 and Th2 lineages. IL-17 contributes to bone destruction in rheumatoid arthritis but is essential in host defense against pathogens that are susceptible to neutrophils. Periodontal disease (PD) is a chronic inflammatory condition initiated by anaerobic oral pathogens such as Porphyromonas gingivalis, and it is characterized by host-mediated alveolar bone destruction due primarily to the immune response. The role of IL-17 in PD is controversial. Whereas elevated IL-17 levels have been found in humans with severe PD, we recently reported that female C57BL/6J mice lacking the IL-17 receptor (IL-17RA(KO)) are significantly more susceptible to PD bone loss due to defects in the chemokine-neutrophil axis (J. J. Yu, M. J. Ruddy, G. C. Wong, C. Sfintescu, P. J. Baker, J. B. Smith, R. T. Evans, and S. L. Gaffen, Blood 109:3794-3802, 2007). Since different mouse strains exhibit differences in susceptibility to PD as well as Th1/Th2 cell skewing, we crossed the IL-17RA gene knockout onto the BALB/c background and observed a similar enhancement in alveolar bone loss following P. gingivalis infection. Unexpectedly, in both strains IL-17RA(KO) female mice were much more susceptible to PD bone loss than males. Moreover, female BALB/c-IL-17RA(KO) mice were defective in producing anti-P. gingivalis immunoglobulin G and the chemokines KC/Groalpha and MIP-2. In contrast, male mice produced normal levels of chemokines and anti-P. gingivalis antibodies, but they were defective in granulocyte colony-stimulating factor upregulation. This study demonstrates a gender-dependent effect of IL-17 signaling and indicates that gender differences should be taken into account in the preclinical and clinical safety testing of anti-IL-17 biologic therapies.
AuthorsJeffrey J Yu, Matthew J Ruddy, Heather R Conti, Kanitsak Boonanantanasarn, Sarah L Gaffen
JournalInfection and immunity (Infect Immun) Vol. 76 Issue 9 Pg. 4206-13 (Sep 2008) ISSN: 1098-5522 [Electronic] United States
PMID18591228 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Bacterial
  • Chemokine CXCL1
  • Chemokine CXCL2
  • Immunoglobulin G
  • Receptors, Interleukin-17
  • Granulocyte Colony-Stimulating Factor
Topics
  • Alveolar Bone Loss (immunology, pathology)
  • Animals
  • Antibodies, Bacterial (immunology)
  • Bacteroidaceae Infections (immunology, pathology)
  • Chemokine CXCL1 (biosynthesis)
  • Chemokine CXCL2 (biosynthesis)
  • Female
  • Granulocyte Colony-Stimulating Factor (biosynthesis)
  • Humans
  • Immunoglobulin G (immunology)
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Mice, Knockout
  • Porphyromonas gingivalis (immunology)
  • Receptors, Interleukin-17 (deficiency, immunology)
  • Sex Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: